CDC73 mutations and parafibromin immunohistochemistry in parathyroid tumors: Clinical correlations in a single-centre patient cohort

Vito Guarnieri, Claudia Battista, Lucia Anna Muscarella, Michele Bisceglia, Danilo De Martino, Filomena Baorda, Evaristo Maiello, Leonardo D'Agruma, Iacopo Chiodini, Celeste Clemente, Salvatore Minisola, Elisabetta Romagnoli, Sabrina Corbetta, Raffaella Viti, Cristina Eller-Vainicher, Anna Spada, Michela Iacobellis, Nazzarena Malavolta, Massimo Carella, Lucie CanaffGeoffrey N. Hendy, David E C Cole, Alfredo Scillitani

Research output: Contribution to journalArticle

Abstract

Objective To determine if molecular and immunohistochemical (IHC) features of the HRPT2/CDC73 gene and its product, parafibromin, predict the natural history of parathyroid malignancy, particularly atypical adenoma, as seen in a single-centre patient cohort. Methods Matched tumor and non-tumor tissues were obtained from 46 patients with parathyroid carcinoma (CA) (n015), atypical adenoma (AA) (n014) and typical adenoma (TA) (n017), as defined by standardized histopathological criteria. Exons and exon-intron boundaries of the CDC73 gene were sequenced to identify germline or somatic mutations. IHC staining for parafibromin was performed and scored as positive if nuclear staining was at least partially IHC-positive. Results Mutations of CDC73 were observed in 9/15 (60 %) CA, 2/14 (14 %) AA, and 1/17 (6 %) TA tumors. A recurrent two basepair mutation in exon 7 - c.679-680delAG - accounted for half of all identified mutations. Absence of parafibromin nuclear staining was noted in 8/12 (67 %) CA, 2/13 (15 %) AA, and 3/17 (18 %) TA tumors. Median follow up times were 88 months for CA, 76 months for AA, and 104 months for TA patients. One patient, a member of a previously reported multiplex family with a germline CDC73 mutation was found to have a second adenoma after removal of an atypical adenoma. Conclusions Molecular screening and IHC are both useful tools in the differential diagnosis of parathyroid tumors, but both have limited sensitivity and specificity. CDC73 mutations and negative immunostaining were common in atypical adenomas, but no local recurrence was observed in any case with successful surgical removal after follow-up periods of 27 to 210 months.

Original languageEnglish
Pages (from-to)411-422
Number of pages12
JournalCellular Oncology
Volume35
Issue number6
DOIs
Publication statusPublished - 2012

    Fingerprint

Keywords

  • Atypical adenoma
  • CDC73
  • HRPT2
  • Parafibromin
  • Parathyroid tumours

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Medicine
  • Oncology
  • Medicine(all)

Cite this